Fouad KHALIL, Mohammed BOUACHRINE, Abdellah EL AISSOUQ, Abdelkrim OUAMMOU

Computational investigation of unsaturated ketone derivatives as MAO-B inhibitors by using QSAR, ADME/Tox, molecular docking, and molecular dynamics simulations

Unsaturated ketone derivatives are known as monoamine oxidase B (MAO-B) inhibitors, a potential drug target for Parkinson’s disease. Here, molecular modeling studies, including 2D-QSAR, ADMET prediction, molecular docking, and MD simulation, were performed on a new series of MAO-B inhibitors. The objective is to identify new MAO-B inhibitors with high inhibitory efficacy. The developed 2D-QSAR model was based on the descriptors of MOE software. The most appropriate model, using the partial least squares regression (PLS regression) method, yielded 0.88 for the determination coefficient (r2 ), 0.28 for the root-mean-square error (RMSE), and 0.2 for the mean absolute error (MAE). The predictive capacity of the generated model was evaluated by internal and external validations, which gave the $Q^2 and R^2 _{test}$ values of 0.81 and 0.71, respectively. The ability of a compound to be orally active was determined using the drug-likeness and ADMET prediction. The results indicate that most of the compounds have moderate pharmacokinetic characteristics without any side effects. Furthermore, the affinity of the ligands (unsaturated ketone derivatives) to the MAO-B receptor was determined using molecular docking. The top conformers were then subjected to MD simulation. This research may pave the way for the development of novel unsaturated ketone derivatives capable of inhibiting the MAO-B enzyme.

PDF

___

1. Shih JC, Chen K, Ridd MJ. MONOAMINE OXIDASE : From Genes to Behavior. Annual Review of Neuroscience 1999; 22: 197–217. doi: 10.1146/annurev.neuro.22.1.197
2. Denney RM. Assignment of genes for human monoamine oxidases A and B to the X chromosome. Journal of Neuroscience Research 1986; 616: 601–616. doi: 10.1016/B978-0-7020-3373-5.00010-1
3. Bach AWJ, Lant NC, Johnsont DL, Abell CW, Bembenek ME et al. cDNA cloning of human liver monoamine oxidase A and B : Molecular basis of differences in enzymatic properties. Proceedings of the National Academy of Sciences 1988; 85: 4934–4938. doi: 10.1073/ pnas.85.13.4934
4. Cesura BAM, Pletscher A. The new generation of monoamine oxidase inhibitors. Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques 1992; 38: 224–225. doi: 10.1007/978-3-0348-7141-9_3
5. Jegham S, George P, Recherche S, Snc DDR, Carrières R. Monoamine oxidase A and B inhibitors. Expert Opinion on Therapeutic Patents Jegham 1998; 8 (9): 1143–1150. doi: 10.1517/13543776.8.9.1143
6. Academy S, Sciences M. The discovery of antidepressants: A winding path. A Pletscher 1991; 47 (1): 4-8. doi: 10.1007/BF02041242
7. D SZM. A clinical overview of monoamine oxidase inhibitors. Psychosomatics 1985; 26 (3): 240-246,251. doi: 10.1016/S0033- 3182(85)72877-0
8. Marin DB, Bierera LM, Lawlorb BA, Ryana TM, Jacobsonc R et al. L-Deprenyl and physostigmine for the treatment of Alzheimer’s disease. Psychiatry Research 1995; 58 (3): 181-189. doi: 10.1016/0165-1781(95)02714-8
9. Jo S, Yarishkin O, Hwang YJ, Chun YE, Park M et al. ARTICLES GABA from reactive astrocytes impairs memory in mouse models of Alzheimer ’ s disease. Nature Publishing Group 2014; 20:886–896. doi: 10.1038/nm.3639
10. Waibel S, Reuter A, Ludolph AC. Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. Journal of Neurology. 2004; 251:1080–1084. doi: 10.1007/s00415-004-0481-5
11. Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL et al. Glide : A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. Journal of Medicinal Chemistry 2004; 47 (7): 1750–1759. doi: 10.1021/jm0310885
12. Fabbri M, Rosa MM, Abreu D, Ferreira JJ. Clinical pharmacology review of safinamide for the treatment of Parkinson’s disease. Future Medicine 2015; 5. doi: 10.2217/nmt.15.46
13. Salum LB, Altei WF, Chiaradia LD, Cordeiro MNS, Canevarolo RR et al. European Journal of Medicinal Chemistry migration inhibitors. European Journal of Medicinal Chemistry 2013; 63:501–510. doi: 10.1016/j.ejmech.2013.02.037
14. Israf DA, Khaizurin TA, Syahida A, Lajis NH, Khozirah S. Cardamonin inhibits COX and iNOS expression via inhibition of p65NFκB nuclear translocation and Iκ-B phosphorylation in RAW 264.7 macrophage cells. Molecular Immunology 2007; 44: 673–679. doi: 10.1016/j.molimm.2006.04.025
15. Mahapatra DK, Asati V, Bharti SK. European Journal of Medicinal Chemistry Chalcones and their therapeutic targets for the management of diabetes : Structural and pharmacological perspectives. European Journal of Medicinal Chemistry 2015; 92: 839–865. doi: 10.1016/j. ejmech.2015.01.051
16. Mallikharjuna Rao Lambu, Suresh Kumar, Syed Khalid Yousuf, Deepak K Sharma, Altaf hussain et al. Medicinal chemistry of dihydropyran based medium ring macrolides related to aspergillides : selective inhibition of PI3K α !. Journal of Medicinal Chemistry 2013; 56 (15): 6136–6145. doi: 10.1021/jm400515c
17. Ramadan M, Sayed E, Hamadah H, El A, Fodah R. European Journal of Medicinal Chemistry Antiobesity, antioxidant and cytotoxicity activities of newly synthesized chalcone derivatives and their metal complexes. European Journal of Medicinal Chemistry 2014; 76:517– 530. doi: 10.1016/j.ejmech.2014.02.021
18. Sinha S, Medhi B, Sehgal R. Chalcones as an Emerging Lead Molecule for Antimalarial Therapy: A Review. Journal of Modern Medicinal Chemistry. 2013; 1:64–77.
19. Sharma H, Patil S, Sanchez TW, Neamati N, Schinazi RF et al. Bioorganic & Medicinal Chemistry Synthesis, biological evaluation and 3D-QSAR studies of 3-keto salicylic acid chalcones and related amides as novel HIV-1 integrase inhibitors. Bioorganic & Medicinal Chemistry. 2011; 19 (6): 2030–2045. doi: 10.1016/j.bmc.2011.01.047
20. Arasappan A, Padilla AI, Jao E, Bennett F, Bogen SL et al. Toward second generation hepatitis C Virus NS3 serine protease inhibitors: discovery of novel P4 modified analogues with improved potency and pharmacokinetic profile. Journal of Medicinal Chemistry 2009; 52: 2806–2817. doi: 10.1021/jm801590u
21. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. Journal of Natural Products 2007; 70 (3): 461– 477. doi: 10.1021/np068054v
22. Scapin G. Structural biology and drug discovery. Current Pharmaceutical Design 2006; 12 (17): 2087–2097. doi: 10.2174/138161206777585201
23. Drie JH. Computer-aided drug design: The next 20 years. Journal of Computer-Aided Molecular Design 2007; 21 (10–11): 591–601. doi: 10.1007/s10822-007-9142-y
24. Zhou H, Liu L, Huang J, Bernard D, Karatas H et al. Structure-based design of high-affinity macrocyclic peptidomimetics to block the menin-mixed lineage leukemia 1 (MLL1) protein-protein interaction. Journal of Medicinal Chemistry 2013; 56 (3): 1113–1123. doi: 10.1021/jm3015298
25. Fung HYJ, Chook YM. Atomic basis of CRM1-cargo recognition, release and inhibition. Seminars in Cancer Biology 2014; 27: 52–61. doi: 10.1016/j.semcancer.2014.03.002
26. Ran X, Liu L, Yang CY, Lu J, Chen Y et al. Design of high-affinity stapled peptides to target the repressor activator protein 1 (RAP1)/ telomeric repeat-binding factor 2 (TRF2) protein-protein interaction in the shelterin complex. Journal of Medicinal Chemistry 2016; 59 (1): 328–334. doi: 10.1021/acs.jmedchem.5b01465
27. Kargbo RB. Novel triterpenone for treatment of viral diseases-HIV inhibitors. ACS Medicinal Chemistry Letters. 2018; 9 (4): 298–299. doi: 10.1021/acsmedchemlett.8b00113
28. Nagasaka M, Ge Y, Sukari A, Kukreja G, Ou SHI. A user’s guide to lorlatinib. Critical Reviews in Oncology/Hematology 2020; 151 (4):102969. Doi: 10.1016/j.critrevonc.2020.102969.
29. Huang HJ, Lee KJ, Yu HW, Chen CY, Hsu CH et al. Structure-based and ligand-based drug design for her 2 receptor. Journal of Biomolecular Structure and Dynamics 2010; 28 (1): 23–37. doi: 10.1080/07391102.2010.10507341
30. Druker B.J. LNB. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia. Journal of Clinical Investigation 2000; 105 (1): 3–7. doi: 10.1172/JCI9083
31. Wlodawer A, Vondrasek J. Inhibitors of HIV-1 protease: A major success of structure-assisted drug design. Annual Review of Biophysics and Biomolecular Structure 1998; 27: 249–284. doi: 10.1146/annurev.biophys.27.1.249
32. Clark DE. What has computer-aided molecular design ever done for drug discovery? Expert Opinion on Drug Discovery 2006; 1 (2): 103–110. doi: 10.1517/17460441.1.2.103
33. Depeursinge A, Racoceanu D, Iavindrasana J, Cohen G, Platon A et al. Fusing visual and clinical information for lung tissue classification in HRCT data. Artificial Intelligence in Medicine 2010; 10: ARTMED1118. doi: 10.1016/j
34. Liu B, Tsutsui M, Taniguchi M. Measuring single-molecule conductance at an Ultra-Low molecular concentration in vacuum. Micromachines 2018; 9 (6): 282. doi: 10.3390/mi9060282
35. Choi JW, Jang BK, Cho N, Park JH, Yeon SK et al. Synthesis of a series of unsaturated ketone derivatives as selective and reversible monoamine oxidase inhibitors. Bioorganic & Medicinal Chemistry 2015; 23 (19): 6486–6496. doi: 10.1016/j.bmc.2015.08.012
36. Tong J, Zhan P, Wang XS, Wu Y. Quionolone carboxylic acid derivatives as HIV-1 integrase inhibitors: Docking-based HQSAR and topomer CoMFA analyses. Journal of Chemometrics 2017; 31 (12): 1–13. doi: 10.1002/cem.2934
37. Clark M, Cramer RD, Van Opdenbosch N. Validation of the general purpose tripos 5.2 force field. Journal of Computational Chemistry 1989; 10 (8): 982–1012. doi: 10.1002/jcc.540100804
38. Caballero J, Saavedra M, Fernández M, González-Nilo FD. Quantitative structure-activity relationship of rubiscolin analogues as δ opioid peptides using comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA). Journal of Agricultural and Food Chemistry 2007; 55 (20): 8101–8104. doi: 10.1021/jf071031h
39. El Aissouq A, Toufik H. QSAR study of isonicotinamides derivatives as Alzheimr’s disease inhibitors using PLS-R and ANN methods. 2019 International Conference on Intelligent Systems and Advanced Computing Sciences (ISACS) 2019; 1–7. doi: 10.1109/ISACS48493.2019.9068919
40. El Aissouq A, Toufik H, Stitou M, Ouammou A, Lamchouri F. In silico design of novel tetra-substituted pyridinylimidazoles derivatives as c-Jun N-Terminal Kinase-3 Inhibitors, Using 2D/3D-QSAR studies, molecular docking and ADMET prediction. International Journal of Peptide Research and Therapeutics 2020; 26: 1335–1351. doi: 10.1007/s10989-019-09939-8
41. El Aissouq A, Chedadi O, Kasmi R, Elmchichi L, En-nahli F et al. Molecular modeling studies of C-Glycosylfavone derivatives as GSK-3β inhibitors based on QSAR and docking analysis. Journal of Solution Chemistry 2021; 50 (5): 808–822. doi: 10.1007/s10953-021-01083-6
42. Zhihua L, Yuzhang W, Bo Z, Bing N, Li W. Toward the quantitative prediction of T-Cell epitopes: QSAR studies on peptides having affinity with the class I MHC molecular HLA-A*0201. Journal of Computational Biology 2005; 11 (4): 683–694. doi: 10.1089/cmb.2004.11.683
43. Kunal R, Supratik K, Rudra, Narayan D. A Primer on QSAR/QSPR Modeling. New York. Springer International Publishing, 2015.
44. Roy PP, Roy K. On some aspects of variable selection for partial least squares regression models. QSAR & Combinatorial Science 2008; 27 (3): 302–313. doi: 10.1002/qsar.200710043
45. Shukla A, Tyagi R, Meena S, Datta D, Srivastava SK et al. 2D- and 3D-QSAR modelling, molecular docking and in vitro evaluation studies on 18β-glycyrrhetinic acid derivatives against triple-negative breast cancer cell line. Journal of Biomolecular Structure and Dynamics 2019; 38 (1): 168–185. doi: 10.1080/07391102.2019.1570868
46. Tropsha A. Best Practices for QSAR Model development, validation, and exploitation. Molecular Informatics 2010; 29: 476–488. doi: 10.1002/ minf.201000061
47. Roy K, Kar S, Das RN. A Primer on QSAR/QSPR Modeling: Fundamental Concepts. Boston, Academic Press, 2015.
48. Golbraikh A, Tropsha A. Beware of $q^2!$ Journal of Molecular Graphics and Modelling 2002; 20 (4): 269–276. doi: 10.1016/S1093-3263(01)00123-1
49. Schu G, Ebert R, Chen J, Wang B, Ku R. External validation and prediction employing the predictive squared correlation coefficient. Journal of Chemical Information and Modeling 2008; 48 (11): 2140–2145.
50. Gramatica P. Principles of QSAR models validation: Internal and external. QSAR and Combinatorial Science 2007; 26 (5): 694–701. doi: 10.1002/qsar.200610151
51. Goudzal A, Aissouq A El, Hamdani H El, Ouammou A. Materials Today: Proceedings QSAR modeling, molecular docking studies and ADMET prediction on a series of phenylaminopyrimidine- ( thio ) urea derivatives as CK2 inhibitors. Materials Today: Proceedings 2020; 31: 1-12. doi: 10.1016/j.matpr.2020.08.044
52. Pires DEV, Blundell TL, Ascher DB. pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. Journal of Medicinal Chemistry 2015; 58 (9): 4066–4072. doi: 10.1021/acs.jmedchem.5b00104
53. Daina A, Michielin O, Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports 2017; 7 (8): 1–13. doi: 10.1038/srep42717
54. Dong X, Zhang ZM, Liu F, Wang W, Yu F et al. Metamorphic rocks of the causes of southeastern Lhasa terrane and the Mesozoic - Cenozoic orogeny. Acta Petrologica Sinica 2012; 28 (6): 1765–1784.
55. Dalvit C, Fasolini M, Flocco M, Knapp S, Pevarello P et al. Spectroscopy Experiments: Detection of High-Affinity Ligands. Journal of Medicinal Chemistry. 2002; 45: 2610–2614. doi: 10.1021/jm011122k
56. Yan B, Gremlich HU, Moss S, Coppola GM, Sun Q et al. A comparison of various FTIR and FT Raman methods: Applications in the reaction optimization stage of combinatorial chemistry. Journal of Combinatorial Chemistry 1999; 1 (1): 46–54. doi: 10.1021/cc980003w
57. El Aissouq A, Chedadi O, Bouachrine M, Ouammou A. Identification of novel SARS-CoV-2 inhibitors: A structure-based virtual screening approach. Journal of Chemistry 2021; 2021: 1-7. doi:10.1155/2021/1901484
58. Kasmi R, Hadaji E, Chedadi O, El Aissouq A, Bouachrine M et al. 2D-QSAR and docking study of a series of coumarin derivatives as inhibitors of CDK (anticancer activity) with an application of the molecular docking method. Heliyon 2020; 6 (March): e04514. doi: 10.1016/j. heliyon.2020.e04514
59. El Mchichi L, El Aissouq A, Kasmi R, Belhassan A, El-Mernissi R et al. In silico design of novel Pyrazole derivatives containing thiourea skeleton as anti-cancer agents using: 3D QSAR, Drug-Likeness studies, ADMET prediction and molecular docking. Materials Today: Proceedings 2021; 45 (8): 7661-7674. doi: 10.1016/j.matpr.2021.03.152
60. Binda C, Khalil A, Li M, Mattevi A, Castagnoli N et al. Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors. Journal of Biological Chemistry 2005; 280 (16): 15761–15766. doi: 10.1074/jbc.M500949200
61. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK et al. Software news and updates AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry 2009; 30 (16): 2785–2791. doi: 10.1002/jcc
62. Trott O, Olson AJ. Software news and update AutoDock vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry 2009; 31 (2): 455–461. doi: 10.1002/jcc
63. Abraham MJ, Murtola T, Schulz R, Páll S, Smith JC et al. Gromacs: High performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 2015; 1–2:19–25. doi: 10.1016/j.softx.2015.06.001
64. Vanommeslaeghe K, Hatcher E, Acharya C, Kundu S, Zhong S et al. CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. Journal of Computational Chemistry 2010; 31 (4): 671–690. doi: 10.1002/jcc.21367
65. Best RB, Zhu X, Shim J, Lopes PEM, Mittal J et al. Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone ϕ , ψ and side-chain χ 1 and χ 2 dihedral angles. Journal of Chemical Theory and Computation 2012; 8 (9): 3257–3273. doi: 10.1021/ct300400x
66. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML et al. Comparison of simple potential functions for simulating liquid water Comparison of simple potential functions for simulating liquid water. The Journal of Chemical Physics 1983; 926 (79). doi: 10.1063/1.445869
67. Wildman SA, Crippen GM. Three-dimensional molecular descriptors and a novel QSAR method. Journal of Molecular Graphics and Modelling 2002; 21(February): 161–170. doi: 10.1016/S1093-3263(02)00147-X
68. Introduction AN, Chemoinformatics TO. An Introduction to Chemoinformatics. Springer, 2007.
69. Sulistyo B, Sudarmanto ARI, Yuswanto A, Susidarti A, Noegrohati SRI. Mole cu la r Mod eling of H um an 3 β-Hy droxy steroid dehydrogenase Type 2: combined homology modeling, docking and QSAR approach (Pemodelan molekular enzim 3β-Hydroxysteroid dehydrogenase tipe 2: pemodelan kombinasi homologi, docking dan pendekatan. Indonesian Journal of Pharmaceutical Sciences 2017; 15 (1): 7–16.
70. Meng-lund H, Kasten G, Tarp K, Poso A, Pantsar T. The use of molecular descriptors in the development of co-amorphous formulations. European Journal of Pharmaceutical Sciences 2018; 119 (2): 31–38. doi: 10.1016/j.ejps.2018.04.014
71. Shahapurkar S, Pandya T, Kawathekar N, Chaturvedi SC. Quantitative structure activity relationship studies of diaryl furanones as selective COX-2 inhibitors. European Journal of Medicinal Chemistry 2004; 39 (4): 383–388. doi: 10.1016/j.ejmech.2003.12.007
72. Bower KM. Analysis of variance (ANOVA) using MINITAB. Journal of Scientific Instruments 2000; 17 (3): 0–5.